Population Council scientists and their partners have found that their proprietary microbicide gel is safe, stable, and can prevent the transmission of multiple sexually transmitted infections in both the vagina and rectum in animals: HIV, herpes simplex virus 2, and human papillomavirus.
22 April 2014 | Eurekalert Medicine & Health
The National Institutes of Health has shown that a study of its vaginal ring for the prevention of HIV came back with mixed results. The ring, which delivers two drugs, was safe for 28 days, but only one of the antiretroviral drugs was effective in protecting against the virus.
10 March 2014 | Fierce Drug Delivery
Experimental vaginal microbicides—products such as gels, films, or flexible rings worn inside the vagina—were the focus of two studies reported Tuesday at the 21st Conference on Retroviruses and Opportunistic Infections.
05 March 2014 | BETA blog
Women who used an injectable contraceptive called DMPA were more likely to acquire HIV than women using a similar product called NET-EN, according to a secondary analysis of data from a large HIV prevention trial called VOICE. The new analysis, conducted by researchers from the NIH-funded Microbicide Trials Network, is the first head-to-head observational study to directly compare differences in HIV risk between users of DMPA and NET-EN.
04 March 2014 | Eurekalert Medicine & Health
Janssen GPH will be responsible for clinical and product development and creating and implementing innovative new access strategies for a growing portfolio of pharmaceuticals, diagnostics, and services for diseases significantly impacting resource-limited countries and emerging markets, and includes bedaquiline for drug-resistant TB, long-lasting injectable rilpivirine for HIV prevention and the dapivirin ring for HIV prevention.
22 January 2014 | Janssen press release
An agreement between the United States Agency for International Development and the Population Council announced Monday for the development of a non-antiretroviral-based compound to block HIV and other sexually transmitted infections could yield a low-risk, easy access product for women in low resource settings in as few as a dozen years, if a promising new compound performs as hoped. That is a big if - the field of microbicide research has seen a roller coaster of raised expectations and dashed hopes over the last decades.
11 January 2014 | Science Speaks
A new intravaginal ring delivers both tenofovir for HIV prevention and levonorgestrel for contraception for 3 months, researchers reported at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition taking place this week in San Antonio. Other studies looked at a novel gel for both vaginal and rectal use containing the antiretroviral IQP-0528, and a bio-adhesive vaginal gel combining tenofovir and the anti-herpes drug acyclovir.
21 November 2013 | HIVandHepatitis.com
Researchers developed a first-of-its-kind microbicide gel formulation that shows promise for safe vaginal and rectal administration to prevent the sexual transmission of human immunodeficiency virus. The DuoGel will deliver ImQuest's antiretroviral compound IQP-0528.
15 November 2013 | Eurekalert Inf Dis
Designing a successful topical microbicide against HIV must balance efficacy and toxicity. Microbicides are intended to cut down the risk for transmission of HIV, and they may give a measure of control to people whose partners do not use condoms.
30 October 2013 | Medscape (requires free registration)
The International Partnership for Microbicides (IPM) announced today that it has received two competitive five-year awards with a combined US$40 million ceiling from the US Agency for International Development (USAID). Both awards aim to advance new HIV prevention tools for women and to help ensure their availability in developing countries where the epidemic has hit hardest.
22 October 2013 | International Partnership for Microbicides